{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+Control&page=2", "query": { "intervention": "Ranibizumab Control", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ranibizumab+Control&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T15:13:25.378Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02349516", "title": "Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy" ], "interventions": [ { "name": "Squalamine Lactate Ophthalmic Solution 0.2%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Starr Muscle", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-02", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-06-01", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02349516" }, { "nct_id": "NCT02296567", "title": "Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Age Related Macular Degeneration" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" }, { "name": "Control Group", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "East Florida Eye Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 80, "start_date": "2014-12", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2015-08-11", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 1, "location_summary": "Stuart, Florida", "locations": [ { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296567" }, { "nct_id": "NCT01134055", "title": "Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "pazopanib eye drops", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "ranibizumab intravitreal injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 510, "start_date": "2010-06-01", "completion_date": "2012-10-01", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 37, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01134055" }, { "nct_id": "NCT01414153", "title": "Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Exudative Age-related Macular Degeneration" ], "interventions": [ { "name": "4.0 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg iSONEP", "type": "DRUG" }, { "name": "0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea", "type": "DRUG" }, { "name": "sham injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lpath, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 158, "start_date": "2012-08", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-10-17", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 44, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01414153" }, { "nct_id": "NCT00891735", "title": "A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 1097, "start_date": "2009-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2013-01-18", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 99, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 91 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00891735" }, { "nct_id": "NCT03203447", "title": "Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Edema", "Retinal Vein Occlusion" ], "interventions": [ { "name": "suprachoroidal CLS-TA", "type": "DRUG" }, { "name": "suprachoroidal sham", "type": "DRUG" }, { "name": "Lucentis or Avastin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clearside Biomedical, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2018-03-05", "completion_date": "2018-12-18", "has_results": true, "last_update_posted_date": "2021-04-23", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 72, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 61 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03203447" }, { "nct_id": "NCT02067013", "title": "Analysis of Aqueous and Vitreous Humor", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Proliferative Diabetic Retinopathy", "Macular Degeneration", "Macular Hole", "Neovascular Glaucoma" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "No Ranibizumab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "California Retina Consultants", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2015-07", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-03-01", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 1, "location_summary": "Santa Barbara, California", "locations": [ { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02067013" }, { "nct_id": "NCT07007065", "title": "Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "Surabgene Lomparvovec (ABBV-RGX-314)", "type": "DRUG" }, { "name": "Ranibizumab Control", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 561, "start_date": "2025-11-05", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 53, "location_summary": "Mesa, Arizona • Sun City, Arizona • Campbell, California + 49 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Campbell", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07007065" }, { "nct_id": "NCT02358889", "title": "Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Choroidal Neovascularization", "Age-related Macular Degeneration" ], "interventions": [ { "name": "hI-con1", "type": "BIOLOGICAL" }, { "name": "ranibizumab", "type": "BIOLOGICAL" }, { "name": "Sham injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Iconic Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 88, "start_date": "2015-02", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 48, "location_summary": "Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Campbell", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358889" }, { "nct_id": "NCT02222610", "title": "Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Radiation Retinopathy" ], "interventions": [ { "name": "0.5 mg ranibizumab", "type": "DRUG" }, { "name": "Targeted Retinal Photocoagulation (TRP)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Greater Houston Retina Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2014-09-23", "completion_date": "2019-03", "has_results": true, "last_update_posted_date": "2021-03-25", "last_synced_at": "2026-09-27T15:13:25.378Z", "location_count": 4, "location_summary": "Dallas, Texas • Houston, Texas • Katy, Texas + 1 more", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Katy", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222610" } ] }